We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker Gains 66.3% in a Year: What's Driving the Rally?
Read MoreHide Full Article
Key Takeaways
BRKR shares gained 66.3% in a year, driven by strong demand in biopharma, diagnostics and mass spectrometry.
First-half 2026 CALID revenues rose to $626.6M, while preclinical imaging orders grew at double-digit rates.
BRKR faces a $134.9M goodwill impairment and currency pressures with 2026 revenues expected at $3.54B-$3.57B.
Bruker Corporation (BRKR - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 66.3% compared with the industry’s 66.4% growth. The S&P 500 composite has increased 18.2% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
BRKR designs and manufactures proprietary life science and materials research systems and associated products. The company serves multiple customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology and in-vitro diagnostics. The company reports through four segments — Bruker Scientific Instruments (BSI) Biosystems, BSI Microbiology and Infection Diagnostics (BMID), BSI NANO, and Bruker Energy & Supercon Technologies (BEST).
Factors Favoring BRKR’s Share Price Growth
Bruker’s share price is trending upward, prompted by the strong demand across biopharma, security detection, molecular diagnostics and mass spectrometry. In the first half of 2026, its former CALID businesses’ revenues were $626.6 million, up from $565.9 million a year earlier and higher by a mid-single-digit percentage at constant exchange rates. Growth was driven by mass spectrometry, including the Tofwerk acquisition, with additional gains in biopharma, security detection and European academic and government markets. Molecular diagnostics also grew, although microbiology was roughly flat.
Additionally, Bruker’s preclinical imaging portfolio serves cancer research, neuroimaging, orthopedics, cardiac imaging and stroke models, with higher-field systems supporting applications that require greater resolution. The first quarter of 2026 included acceptance of an 18 Tesla preclinical MRI system, while first-half 2026 NMR preclinical and preclinical imaging orders both rose at double-digit rates year over year. These order trends show continued customer investment despite broader academic funding weakness.
From a solvency viewpoint, Bruker exited the second quarter of 2026 with cash and cash equivalents of $184.9 million compared with $298.8 million at the end of 2025. Meanwhile, the current portion of long-term debt and finance lease obligations was only $10.1 million, well below the company’s cash balance. Bruker also had total current assets of $2.23 billion compared with current liabilities of $1.20 billion as of June 30, 2026, supporting its near-term solvency position. Overall, limited near-term debt maturities and adequate current asset coverage provide financial flexibility.
Image Source: Zacks Investment Research
Factors That May Offset BRKR’s Gains
Bruker is reorganizing its scientific instruments businesses while addressing underperforming assets. Second-quarter 2026 GAAP results included a $134.9 million noncash goodwill impairment tied to automation and spatial biology businesses that continued to generate operating losses. The new BSI Biosystems restructuring plan is expected to cost $12-$15 million and be completed during 2026. The reorganization also triggered another interim goodwill impairment review for the third quarter. These actions may improve portfolio focus, but they add execution demands as Bruker integrates operations.
Also, Bruker’s global revenue base keeps reported growth and earnings sensitive to exchange-rate changes. The company reduced its full-year 2026 expected currency revenue benefit to about 0.5% from 1.5%. It now assumes an approximately $0.10, or 5%, currency drag on non-GAAP EPS. The revised currency outlook lowered expected full-year revenues to $3.54-$3.57 billion while EPS guidance remained $2.10-$2.15, showing that rate movements can alter reported growth even when underlying demand assumptions are unchanged.
A Look at BRKR’s Estimates
The Zacks Consensus Estimate for 2026 EPS has remained unchanged at $2.12 in the past 30 days.
The company has an estimated long-term EPS growth rate of 15.4%, in line with the industry’s growth rate.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
OPKO Health, sporting a Zacks Rank of 1 at present, has an estimated 2026 earnings growth rate of 23.3% compared with the industry’s 16.6% growth. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 95.1%. OPK shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Bruker Gains 66.3% in a Year: What's Driving the Rally?
Key Takeaways
Bruker Corporation (BRKR - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 66.3% compared with the industry’s 66.4% growth. The S&P 500 composite has increased 18.2% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
BRKR designs and manufactures proprietary life science and materials research systems and associated products. The company serves multiple customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology and in-vitro diagnostics. The company reports through four segments — Bruker Scientific Instruments (BSI) Biosystems, BSI Microbiology and Infection Diagnostics (BMID), BSI NANO, and Bruker Energy & Supercon Technologies (BEST).
Factors Favoring BRKR’s Share Price Growth
Bruker’s share price is trending upward, prompted by the strong demand across biopharma, security detection, molecular diagnostics and mass spectrometry. In the first half of 2026, its former CALID businesses’ revenues were $626.6 million, up from $565.9 million a year earlier and higher by a mid-single-digit percentage at constant exchange rates. Growth was driven by mass spectrometry, including the Tofwerk acquisition, with additional gains in biopharma, security detection and European academic and government markets. Molecular diagnostics also grew, although microbiology was roughly flat.
Additionally, Bruker’s preclinical imaging portfolio serves cancer research, neuroimaging, orthopedics, cardiac imaging and stroke models, with higher-field systems supporting applications that require greater resolution. The first quarter of 2026 included acceptance of an 18 Tesla preclinical MRI system, while first-half 2026 NMR preclinical and preclinical imaging orders both rose at double-digit rates year over year. These order trends show continued customer investment despite broader academic funding weakness.
From a solvency viewpoint, Bruker exited the second quarter of 2026 with cash and cash equivalents of $184.9 million compared with $298.8 million at the end of 2025. Meanwhile, the current portion of long-term debt and finance lease obligations was only $10.1 million, well below the company’s cash balance. Bruker also had total current assets of $2.23 billion compared with current liabilities of $1.20 billion as of June 30, 2026, supporting its near-term solvency position. Overall, limited near-term debt maturities and adequate current asset coverage provide financial flexibility.
Image Source: Zacks Investment Research
Factors That May Offset BRKR’s Gains
Bruker is reorganizing its scientific instruments businesses while addressing underperforming assets. Second-quarter 2026 GAAP results included a $134.9 million noncash goodwill impairment tied to automation and spatial biology businesses that continued to generate operating losses. The new BSI Biosystems restructuring plan is expected to cost $12-$15 million and be completed during 2026. The reorganization also triggered another interim goodwill impairment review for the third quarter. These actions may improve portfolio focus, but they add execution demands as Bruker integrates operations.
Also, Bruker’s global revenue base keeps reported growth and earnings sensitive to exchange-rate changes. The company reduced its full-year 2026 expected currency revenue benefit to about 0.5% from 1.5%. It now assumes an approximately $0.10, or 5%, currency drag on non-GAAP EPS. The revised currency outlook lowered expected full-year revenues to $3.54-$3.57 billion while EPS guidance remained $2.10-$2.15, showing that rate movements can alter reported growth even when underlying demand assumptions are unchanged.
A Look at BRKR’s Estimates
The Zacks Consensus Estimate for 2026 EPS has remained unchanged at $2.12 in the past 30 days.
The company has an estimated long-term EPS growth rate of 15.4%, in line with the industry’s growth rate.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , OPKO Health (OPK - Free Report) and Teleflex (TFX - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPKO Health, sporting a Zacks Rank of 1 at present, has an estimated 2026 earnings growth rate of 23.3% compared with the industry’s 16.6% growth. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 95.1%. OPK shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.